SB2811 Summary

• Excludes specific opioid antagonists (naloxone, naltrexone, nalmefene, nalbuphine, butorphanol, dextrorphan, and apomorphine) from Schedule I controlled substances classification.

• Allows practitioners to prescribe Schedule III, IV, or V narcotic drugs FDA-approved for maintenance or detoxification treatment if registered with the Drug Enforcement Administration and complying with federal regulations.

• Permits direct administration (not prescribing) of narcotic drugs by DEA-registered treatment programs for opioid-dependent persons undergoing maintenance or detoxification.

• Authorizes non-registered physicians to administer (not prescribe) narcotic drugs for acute withdrawal relief for maximum three days with no more than one day's medication per administration.

• Adds new synthetic cannabinoids and stimulants (including specific cathinone derivatives and indazole compounds) to Schedule I controlled substances; adds dronabinol oral solution to Schedule IV.

• Effective date: July 1, 3000.